News | August 20, 2012

Abbott Announces CE Mark and European Launch of Next-Generation Xience Xpedition Drug-Eluting Stent

August 20, 2012 — Abbott today announced that the Xience Xpedition everolimus-eluting coronary stent system received CE mark in Europe for the treatment of coronary artery disease (CAD), and the company will immediately launch the product in CE-mark countries.

Xience Xpedition features a new stent delivery system designed to optimize acute performance, particularly in challenging coronary anatomies. It is supported by the clinical evidence of the Xience family of stents, including data from more than 45,000 patients across more than 100 studies with long-term outcomes out to five years. Xience Xpedition is available with a broad range of indications, including use with a minimum duration of three months of dual anti-platelet therapy (DAPT).

"The extraordinary deliverability of the new Xience Xpedition drug-eluting stent system allows physicians to treat particularly complex coronary disease with great ease and confidence," said Evald H. Christiansen, M.D., Ph.D., interventional cardiologist, Aarhus University Hospital, Skejby, Denmark, who treated the first patient with Xience Xpedition. "Supported by robust clinical evidence from the SPIRIT family of trials, and with a broad range of indications, Xience Xpedition is an important advancement in drug-eluting stent technology."

The Xience family of stents maintains one of the broadest ranges of CE mark indications of drug-eluting stents on the market in Europe. Specifically, Xience Xpedition has indications to treat patients with complex disease such as diabetes, as well as an indication for a minimum duration of three months of DAPT. This indication represents an important advantage, as three months of DAPT is the shortest duration required for any major drug-eluting stent offered in Europe. Long-term compliance to DAPT can be a challenge for patients and can lead to additional safety risks such as increased bleeding events. In addition, having a shorter DAPT duration after stent implantation may be beneficial in case a patient needs to interrupt or discontinue the medication prior to surgery or for other considerations.

"With Xience Xpedition's excellent deliverability, broad size matrix and the option to discontinue or interrupt DAPT after three months, physicians in Europe now have a new, comprehensive offering to address the challenges of treating patients with complex coronary artery disease," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, medical affairs, and chief medical officer of Abbott Vascular. "With Xience Xpedition, Abbott continues its commitment to advancing drug-eluting stent technology to improve product performance and patient outcomes."

The stent is available in one of the broadest size matrices on the European market, with diameters ranging from 2.25 to 4 mm, including a unique 3.25 mm diameter, and lengths from 8 to 38 mm.

For more information: www.abbott.com

Related Content

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents | November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init